Physician profile
William D Shipman
NPI 1073142238
$18,568.23
in general payments reported to CMS, 2019-2025
24 companies · $17K in 2025
The $17K reported for 2025 was more than what 94% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,263 · 2025: $17K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $12K · Food and Beverage: $5,005 · Travel and Lodging: $1,464 · Education: $99.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $12,000.00 |
| Food and Beverage | $5,004.63 |
| Travel and Lodging | $1,463.64 |
| Education | $99.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $10,327.25 | 2024-2025 | |
| Incyte Corporation | $2,941.08 | 2025 | Opzelura |
| Ucb, INC. | $2,086.14 | 2024-2025 | Bimzelx |
| Genzyme Corporation | $613.04 | 2024-2025 | |
| Arcutis Biotherapeutics, INC. | $398.18 | 2025 | Zoryve |
| Leo Pharma INC. | $377.12 | 2024-2025 | Adbry, Anzupgo |
| Abbvie INC. | $342.07 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $299.30 | 2024-2025 | Dupixent |
| Sun Pharmaceutical Industries INC. | $208.32 | 2025 | |
| Lilly USA, LLC | $200.79 | 2024-2025 | Ebglyss, Taltz |
| Pfizer INC. | $126.53 | 2025 | |
| Amgen INC. | $104.97 | 2024-2025 | Otezla, Otezla |
| Janssen Biotech, INC. | $82.79 | 2024-2025 | Tremfya |
| Ani Pharmaceuticals, INC. | $81.64 | 2025 | Veregen, Oxistat |
| Dermavant Sciences, INC. | $78.60 | 2024 | Vtama |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $66.95 | 2025 | Nemluvio |
| Strata Skin Sciences, INC. | $59.71 | 2024-2025 | Xtrac |
| E.R. Squibb & Sons, L.L.C. | $32.15 | 2024-2025 | Sotyktu |
| Vertex Pharmaceuticals Incorporated | $32.01 | 2025 | |
| Botanix Sb INC | $29.60 | 2025 | Sofdra |
| Almirall LLC | $26.00 | 2024 | Seysara |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.91 | 2025 | Spevigo |
| Organogenesis INC. | $16.51 | 2025 | Cygnus Dual |
| Verrica Pharmaceuticals INC. | $13.57 | 2025 | Ycanth |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Shipman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.